22 Sep Evaluating Clinical Evidence and Patient Selection in First-Line HER2+ GEA Treatment
First-line treatment options for HER2-positive gastroesophageal adenocarcinoma (GEA) are rapidly evolving with new clinical evidence emerging to compare targeted therapies, chemotherapy, and immunotherapy across various patient populations. Given that a HER2-positive metastatic GEA designation does not by itself determine the appropriate first-line treatment for individual patients, a review of key clinical trials, biomarkers for molecularly targeted agents, disease-related characteristics, and patient-related factors is essential to help healthcare professionals evaluate available evidence and select optimal first-line regimens. According to the NCI (National Cancer Institute), HER2-positive gastric and gastroesophageal junction adenocarcinomas represent a distinct molecular subset for which targeted therapy has significantly changed the treatment landscape over the past decade, with ongoing clinical trials continuing to refine optimal combinations and sequencing strategies.
[caption id="attachment_76158" align="aligncenter" width="500"] Photo by Ivan S[/caption]